Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

21. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) ) and salmeterol (50 microg) administered twice daily from a single discus (FP-S); fluticasone propionate (FP; 100 microg); and montelukast (MO; 10 mg). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged 15 years or older with a diagnosis of asthma, as defined by the American Thoracic Society, for at least 6 months. Patients were required to demonstrate a pre-dose forced expiratory volume in one second (FEV1) of 50 to

NHS Economic Evaluation Database.2004

22. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) administered via a single Diskus inhaler device twice daily. The other was an alternative strategy consisting of FP 100 microg twice daily via a Diskus inhaler plus oral montelukast (MON) 10 mg once daily. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged more than 15 years who had had asthma for at least 6 months and had been taking low-to-moderate doses of an ICS for at least 30 days before screening. At the time

NHS Economic Evaluation Database.2004

24. A clinical review of montelukast in the treatment of seasonal allergic rhinitis

A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis Gonyeau M J, Partisano A M CRD summary This review aimed to compare the efficacy of montelokast with current therapies for seasonal allergic rhinitis. The authors concluded that there was no evidence to support the use of montelokast (alone or in combination (...) with antihistamines) over intranasal corticosteroids. Limitations in the review methods and the reporting of included studies mean that these conclusions should be viewed with caution. Authors' objectives To assess the efficacy of montelukast in comparison with current therapies for seasonal allergic rhinitis. Searching MEDLINE and EMBASE were searched (1990 to week 8, 2003); the search terms were reported. Only studies published in the English language were included. Study selection Study designs of evaluations

DARE.2003

25. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. 14563743 2003 10 17 2003 11 06 2015 11 19 1756-1833 327 7420 2003 Oct 18 BMJ (Clinical research ed.) BMJ Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. 891 To assess the effect of montelukast (...) versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one

BMJ2003 Full Text: Link to full Text with Trip Pro

26. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P Record Status This is a critical (...) the Diskus device versus montelukast (MONT; 10 mg) once daily, for 12 weeks. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients suffering from asthma for at least 6 months, who had been treated with an oral or inhaled short-acting beta2-agonist on a scheduled, or as-needed basis for at least 6 weeks before screening. The patients were required to have a forced expiratory volume in 1 second (FEV1) of between 50 and 80

NHS Economic Evaluation Database.2002

27. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Stempel D A, O'Donnell J C, Meyer J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative treatments for patients with moderate persistent asthma were examined. The treatments were inhaled corticosteroids (ICSs) used concurrently with salmeterol (ICS+SAL) or montelukast (ICS+MON). A third comparator, inhaled fluticasone propionate plus SAL (FP+SAL), was also considered. Type of intervention Treatment. Economic study

NHS Economic Evaluation Database.2002

28. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Pathak D S, Davis E A, Stanford R H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology was controller therapy for patients with asthma. The comparators were inhaled corticosteroids and leukotriene modifiers in real world clinical practice. The authors compared fluticasone propionate (44 or 110 microg) with oral zafirlukast (20 mg) and montelukast

NHS Economic Evaluation Database.2002

29. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients.

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. 10398629 1999 08 26 1999 08 26 2014 06 15 0959-8138 319 7202 1999 Jul 10 BMJ (Clinical research ed.) BMJ Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. 87-90 To determine the ability of montelukast, a leukotriene receptor antagonist (...) , to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients. Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks. 23 academic asthma centres in United States, Canada, and Europe. 226

BMJ1999 Full Text: Link to full Text with Trip Pro

30. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. 9555757 1998 04 23 1998 04 23 2016 10 17 0098-7484 279 15 1998 Apr 15 JAMA JAMA Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. 1181-6 Leukotrienes are important mediators of asthma by causing bronchoconstriction, mucous secretion, and increased vascular permeability. Studies using (...) compounds that block leukotrienes have demonstrated improvement in asthma control in adults and adolescents, but children younger than 12 years, for whom asthma is the most common chronic disease, have not been studied. To determine the clinical effect of montelukast, a leukotriene receptor antagonist, in 6- to 14-year-old children with asthma. Eight-week, multicenter, randomized, double-blind study. Forty-seven outpatient centers at private practices and academic medical centers in the United States

JAMA1998

31. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction.

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. 9664090 1998 07 16 1998 07 16 2015 11 19 0028-4793 339 3 1998 Jul 16 The New England journal of medicine N. Engl. J. Med. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. 147-52 Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control (...) of asthma. We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patients against exercise-induced bronchoconstriction. We randomly assigned 110 patients (age, 15 to 45 years) with mild asthma and a decrease in the forced expiratory volume in one second (FEV1) of at least 20 percent after exercise on two occasions during a placebo run-in period to receive 10 mg of montelukast (54 patients) or placebo (56 patients) once daily at bedtime for 12 weeks in a double-blind

NEJM1998